Oncogenic signalling crosstalk between MYD88 and CD79B mutations

淋巴瘤是一种淋巴细胞的血癌，它是由于不受控制的生长和生存造成的。DNA测序的出现表明，许多淋巴瘤同时携带两个信号分子MYD88和CD79B的突变。该项目将研究这些突变蛋白如何协同失调信号，以了解这种疾病的发病机制。它还将加强使用一线药物的理由，并确定新的治疗目标。

Lymphoma is a blood cancer of lymphocytes, which results from uncontrolled growth and survival. The advent of DNA sequencing revealed that many lymphomas carry concurrent mutations in two signalling molecules, MYD88 and CD79B. The project will investigate how these mutant proteins cooperatively dysregulate signalling to understand the pathogenesis of this disease. It will also reinforce the rationale to use front-line drugs and identify new therapeutic targets.